Vaccine Development
ARMR Sciences Advances Fentanyl Vaccine Toward Human Trials with Private Placement
ARMR Sciences Inc. completed a private placement financing led by Joseph Gunnar & Co. to advance its preventive fentanyl vaccine toward human trials, aiming to address the synthetic drug crisis.
GeoVax Advances U.S. Mpox Vaccine Production Amid California Clade 1 Outbreak
The emergence of locally transmitted Clade 1 mpox cases in California highlights critical vulnerabilities in America's single-source vaccine supply chain, prompting GeoVax to accelerate development of domestic manufacturing capabilities with EMA-endorsed regulatory pathways.
GeoVax Reaffirms Commitment to Vaccine Safety Amid Development of GEO-CM04S1 for Immunocompromised Patients
GeoVax Labs emphasizes its evidence-based approach to vaccine safety and the advancement of GEO-CM04S1, a COVID-19 vaccine designed for vulnerable populations with weakened immune systems who respond poorly to current options.
GeoVax to Present Pipeline Updates at H.C. Wainwright Investment Conference
GeoVax Labs will showcase progress on its Mpox/smallpox, COVID-19, and cancer immunotherapy programs at the upcoming H.C. Wainwright conference, highlighting advancements in vaccine development and manufacturing capabilities.
GeoVax Accelerates GEO-MVA Vaccine Development Amid Global Mpox Crisis
GeoVax Labs, Inc. is expediting the development of its GEO-MVA Mpox vaccine in response to a global surge in cases and the WHO's reaffirmation of Mpox as a public health emergency, highlighting the urgent need for scalable and equitable vaccine solutions.
GeoVax Explores Needle-Free Vaccine Delivery with Vaxxas Technology
GeoVax Labs, Inc. initiates a research program to evaluate the potential of a needle-free, self-administered GEO-MVA vaccine using Vaxxas' HD-MAP technology, aiming to enhance global immunization efforts.
Experimental mRNA Vaccine Shows Promise in Enhancing Cancer Immunotherapy
Researchers have discovered that an experimental mRNA vaccine could significantly improve the effectiveness of immunotherapy in fighting tumors, marking a potential advancement towards universal cancer vaccines.
GeoVax Advances Mpox Vaccine Development Amid Global Outbreak Concerns
GeoVax Labs accelerates its GEO-MVA vaccine candidate development following EMA's streamlined approval pathway, addressing the urgent need for diversified Mpox vaccine supply as global outbreaks expand.
GeoVax to Showcase Vaccine and Cancer Therapy Progress at Emerging Growth Conference
GeoVax Labs, Inc. will present updates on its GEO-MVA, GEO-CM04S1, and Gedeptin® programs at the Emerging Growth Conference, highlighting advancements in vaccine development and cancer therapy.
GeoVax Advances Mpox Vaccine Development Amid Rising Global Cases
GeoVax Labs accelerates its GEO-MVA vaccine development for Mpox and smallpox, responding to global health threats and regulatory advancements.
GeoVax Advances Mpox Vaccine Development Amid WHO's Global Health Emergency Declaration
GeoVax Labs, Inc. is responding to the WHO's declaration of Mpox as a global public health emergency by advancing its GEO-MVA vaccine, aiming to address the urgent need for diversified vaccine supply and enhanced pandemic preparedness.
Senate Bipartisan Initiative Aims to Revitalize U.S. Vaccine Manufacturing Capabilities
GeoVax Labs supports a Senate initiative to onshore critical medical manufacturing, highlighting the national push to rebuild domestic vaccine production and enhance public health preparedness through innovative MVA vaccine platforms.
GeoVax Develops Multi-Antigen COVID-19 Vaccine Targeting Immunocompromised Populations
GeoVax's innovative GEO-CM04S1 vaccine addresses critical gaps in COVID-19 immunization strategies by offering broad, durable protection for vulnerable populations as HHS shifts towards risk-based vaccine recommendations.
Soligenix Advances COVID-19 Vaccine Candidate CiVax Amid Ongoing Global Health Threat
Soligenix is developing CiVax, a heat-stable COVID-19 vaccine candidate, in response to persistent global health risks from the virus, with recent preclinical studies showing promising protection against multiple variants.
GeoVax's New Vaccine Development Aims to Address Critical U.S. Biosecurity Gap
GeoVax's development of a domestic Mpox and smallpox vaccine represents a significant step toward reducing U.S. dependence on foreign vaccine manufacturers, addressing a major national security vulnerability exposed during the 2022 Mpox outbreak.